The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.

The latest price target for Bellerophon Therapeutics (NASDAQ: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 390.68% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics (NASDAQ: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.41, which is out of the analyst’s predicted range.